(Updated - December 13, 2021 4:41 AM EST)

UBS analyst Colin Bristow upgraded Pfizer (NYSE: PFE) from Neutral to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments Hot Upgrades Upgrades

Pfizer’s (PFE) $6.7B Arena Acquisition is Priced Reasonably, May Offer Additional Upside, Pfizer Making Good Use of Cash – AnalystDecember 13, 2021 9:30 AM Low Valuations to Drive Pharma M&A in 2022 - AnalystDecember 13, 2021 8:50 AM Pfizer (PFE) to Buy Arena Pharmaceuticals (ARNA) in a $6.7 Billion Deal, Pays a 100% Premium; Seen as the First of Many AcquisitionsDecember 13, 2021 6:41 AM Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene TherapyDecember 12, 2021 4:30 PM Pfizer (PFE) Raises Quarterly Dividend 2.6% to $0.40; 3% YieldDecember 10, 2021 12:01 PM Pfizer Declares First-Quarter 2022 DividendDecember 10, 2021 12:00 PM Boosters give 70-75% Omicron protection, U.K. study shows - BloombergDecember 10, 2021 11:46 AM Pfizer's (PFE) Cibinqo Approved in EU for Treatment of Adults with Moderate-to-Severe Atopic DermatitisDecember 10, 2021 9:27 AM European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic DermatitisDecember 10, 2021 9:27 AM Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- BreasDecember 10, 2021 8:12 AM Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast CancerDecember 10, 2021 8:10 AM Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast CancerDecember 10, 2021 8:10 AM Pfizer (PFE) PT Raised to $54 at BarclaysDecember 10, 2021 4:36 AM CDC Expands Booster Recommendations To 16-and-17-year-olds - BloombergDecember 9, 2021 2:30 PM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and OlderDecember 9, 2021 12:15 PM Pfizer (PFE), BioNTech (BNTX) Confirm U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and OlderDecember 9, 2021 12:07 PM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and OlderDecember 9, 2021 12:07 PM U.S. makes 16- and 17-year-olds eligible for COVID-19 boostersDecember 9, 2021 11:38 AM FDA Expands Eligibility for Pfizer (PFE) -BioNTech (BNTX) COVID-19 Booster Dose to 16- and 17-Year-OldsDecember 9, 2021 11:22 AM uniQure's (QURE) HOPE B Data In-Line With Expectations, Potential Peak Royalties of $485M - AnalystDecember 9, 2021 8:44 AM BioNTech (BNTX) and Pfizer (PFE) Beneficiaries From Lower Omicron Vaccine Efficacy - SVB Leerink December 9, 2021 6:28 AM